Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152073 | 1.00 | MAP3K5 (0.77) | MAP3K5 | |
| SCHEMBL2301751 | 1.00 | MAP3K5 (0.77) | MAP3K5 | |
| SCHEMBL2298977 | 0.89 | MAP3K5 (0.69) | MAP3K5 | |
| SCHEMBL2298812 | 0.87 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL2298807 | 0.87 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL14152671 | 0.87 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL2298473 | 0.85 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL2298474 | 0.85 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL14151413 | 0.81 | MAP3K5 (0.51) | MAP3K5 | |
| SCHEMBL14152322 | 0.81 | MAP3K5 (0.51) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403819-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20140329850-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA CALIFORNIA, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8802695-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-12 | — | — | US | disclosed |
| EP-2531501-B1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-20120316194-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| EP-2531501-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097079-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329850-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | MAP3K5 8/4885 |
| US-20120316194-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | MAP3K5 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.